Wave Life Sciences (WVE) Current Deferred Revenue (2014 - 2026)

Wave Life Sciences (WVE) has 12 years of Current Deferred Revenue data on file, last reported at $9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 83.61% year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (down 83.61% YoY), and the FY2025 full-year result was $44.4 million, down 32.64% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $9.4 million, down from $44.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $150.1 million in Q4 2023 and bottomed at $9.4 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $57.3 million (2025), against an average of $74.3 million.
• The widest annual swing landed in 2023, when Current Deferred Revenue soared 375.5%; it then plunged 83.61% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $31.6 million in 2022, then jumped by 375.5% to $150.1 million in 2023, then slumped by 56.04% to $66.0 million in 2024, then sank by 32.64% to $44.4 million in 2025, then slumped by 78.86% to $9.4 million in 2026.
• The last three Current Deferred Revenue figures came in at $9.4 million (Q1 2026), $44.4 million (Q4 2025), and $46.5 million (Q3 2025), per Business Quant data.

Peer Comparison